Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03081455 · ClinicalTrials.gov registry record
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 145
- Enrollment target
NCT03081455: Completed study, sponsored by Myriad Genetic Laboratories.
NCT03081455 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03081455 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
A prospective, non-interventional study to evaluate the impact of a process engineering intervention on screening and testing outcomes for common hereditary cancer syndromes in community-based OB/GYN settings.
Primary Outcome
The percentage of previously untested patients meeting guidelines who are offered genetic testing on site.
Interventions
- DIAGNOSTIC_TEST Diagnostic Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2017-08-04 |
What the finished NCT03081455 record still lists
NCT03081455 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic Test is the first listed.
NCT03081455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03081455 about?
NCT03081455 is a clinical study titled "Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes". A prospective, non-interventional study to evaluate the impact of a process engineering intervention on screening and testing outcomes for common hereditary cancer syndromes in community-based OB/GYN settings.
What is the current status of trial NCT03081455?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2017-02-13. Estimated completion is 2017-08-04.
What interventions are being tested in trial NCT03081455?
The interventions under investigation include: Diagnostic Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03081455?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI